DIAFERT Trademark

Trademark Overview


On Thursday, March 14, 2019, a trademark application was filed for DIAFERT with the United States Patent and Trademark Office. The USPTO has given the DIAFERT trademark a serial number of 88339989. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, August 17, 2020. This trademark is owned by Femalon S.P.R.L.. The DIAFERT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, pharmaceutical preparations for use in the treatment of glabellar lines, facial wrinkles, facial asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma agents and decongestants; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; ora...
diafert

General Information


Serial Number88339989
Word MarkDIAFERT
Filing DateThursday, March 14, 2019
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, August 17, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, pharmaceutical preparations for use in the treatment of glabellar lines, facial wrinkles, facial asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma agents and decongestants; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing pharmaceutical preparations; pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; pharmaceutical preparations and medicines for the treatment of sensory organ disorders; pharmaceutical preparations and medicines for the treatment of central nervous system disorders; pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; pharmaceutical preparations and medicines for the treatment of circulatory system disorders; pharmaceutical preparations and medicines for the treatment of cardiovascular diseases and high blood pressure; pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; pharmaceutical preparations for supporting, encouraging and promoting bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; antibiotics; antifungal preparations; antivirals; antiprotozoans, namely, pharmaceutical preparations for treating infections caused by protozoa; pharmaceutical preparations for the prevention and treatment of bacterial infections; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS (central nervous system) disorders, neurological disorders, neurodegenerative disorders and depression; neuroprotective agent, namely, pharmaceutical preparations to help prevent or reduce damage to the brain or spinal cord; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents, namely, pharmaceutical preparations for dilating blood vessels; pharmaceutical preparations for the treatment of hypothyroidism; pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenating creams, rehydrating creams and lotions for the face and body, excluding iron preparations for pharmaceutical use and iron preparations as food supplements

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 2, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameFemalon S.P.R.L.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGrĂ¢ce-Hollogne 4460
BE

Trademark Events


Event DateEvent Description
Monday, August 17, 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, August 17, 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, February 4, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, February 4, 2020FINAL REFUSAL E-MAILED
Tuesday, February 4, 2020FINAL REFUSAL WRITTEN
Monday, January 13, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 13, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 9, 2020ASSIGNED TO LIE
Tuesday, December 17, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 13, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 13, 2019NON-FINAL ACTION E-MAILED
Friday, December 13, 2019NON-FINAL ACTION WRITTEN
Thursday, November 21, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 21, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 21, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 29, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 29, 2019NON-FINAL ACTION E-MAILED
Wednesday, May 29, 2019NON-FINAL ACTION WRITTEN
Thursday, May 23, 2019ASSIGNED TO EXAMINER
Tuesday, April 2, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, March 18, 2019NEW APPLICATION ENTERED IN TRAM